LABCORP HOLDINGS INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $14.0B |
| Gross margin | 28.8% |
| Operating income | $1.4B |
| Net income | $876.5M |
| Diluted EPS | $10.46 |
| Cash & equivalents | $532.3M |
| Total assets | $18.4B |
| Long-term debt | $5.1B |
Key takeaway
Labcorp reported $13.95 billion in revenue and $876.5 million in net income for fiscal 2025, driven by its Diagnostics (Dx) and Biopharma Laboratory Services (BLS) segments.
🔒 4 more takeaways in the full analysis
Beneath the surface
Cash fell by nearly $986.4 million year-over-year (per the cash flow reconciliation), while long-term debt remained around $5.08 billion, meaning net debt is roughly $4.55 billion versus the $532.3 million cash cushion highlighted in the headline table.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for LH.
Read the full analysis free Free account · 5 full analyses included · no card required